Nothing else is going on, so here’s a really shallow Hall of Fame thought:
I think it’s almost certain — like, 99.9% certain — that there is already a member of the Hall of Fame who used performance enhancing drugs. Not just greenies, but 1980s-90s-2000s-style steroids, HGH and all of that stuff that causes everyone so much consternation. I even have a couple of ideas of players who may have — guys who aren’t normally mentioned in these conversations — though I won’t say their names for risk that someone take my baseless speculation as some sort of actual information, which it is not.
But if I had a genie who granted me three wishes, I’d use one of the wishes to wish for a million more wishes. Then, with one of those million more wishes, I’d wish that one of those Hall of Fame players announce today that, yes, he was juiced to the gills. No apologies, no explanations, just a “yeah, I was totally ‘roided up,” after which he drops the mic and goes back to hunting, fishing, signing autographs and whatever else he does in his retirement.
Wouldn’t it just make everyone’s head explode?
And while it is a shallow thought, it’s not just some hypothetical thing. Because one day we’re going to learn about a Hall of Famer who used PEDs, at which point one of the leading arguments against voting in the Barry Bonds and Roger Clemens of the world is going to make even less sense than it already does.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.